Eltrombopag price & Cost

Eltrombopag price depends on the brand and location. Usually, the generic is an expensive medication.

It is marketed under different brand names depending on the region. Here’s a list of its brand names: 

Available Brands and Eltrombopag Price List:

In other countries, prices might be lower or higher depending on their healthcare system. So it’s important to check your local pharmacies or online dispensaries for the most accurate pricing. 

Eltrombopag Indications:

Eltrombopag is a medicine used to treat certain blood disorders. It belongs to a class of drugs known as thrombopoietin receptor agonists. It works by stimulating the production of platelets in the bone marrow, which can help reduce the risk of bleeding in people with low platelet counts.

Here are some key uses:

1. Chronic Immune Thrombocytopenia:  Eltrombopag is often prescribed to adults and children who have had their spleen removed and have low platelet counts despite other treatments.

2. Aplastic Anemia:  It is also used to treat certain types of aplastic anemia, a condition in which the bone marrow does not make enough new blood cells.

3. Thrombocytopenia due to Hepatitis C:  The generic is sometimes used to increase platelet counts in patients with chronic hepatitis C, enabling them to tolerate antiviral treatment.

Eltrombopag drug class:

thrombopoietin receptor agonist.

Mechanism of action (moa):

Eltrombopag’s mechanism of action (MOA) involves stimulation of the thrombopoietin receptor (TPO-R), also known as the c-Mpl receptor, located on the surface of megakaryocytes and their progenitors in the bone marrow.

Dosing guidelines:

• Chronic Immune Thrombocytopenia (ITP):

  • Adults & Pediatric (≥6 years): Start with 50 mg once daily. Adjust dose based on response; maximum 75 mg/day.
  • Pediatric (1-5 years): Start with 25 mg once daily.

• Severe Aplastic Anemia:

  • Adults: Start with 50 mg once daily. Adjust dose based on response; maximum 150 mg/day.

• Hepatitis C-Associated Thrombocytopenia:

  • Adults: Start with 25 mg once daily. Increase dose based on platelet counts; maximum 100 mg/day.

Administration:

• It should be taken on an empty stomach (1 hour before or 2 hours after a meal) to improve absorption.
• Avoid taking Eltrombopag with dairy products or calcium-rich foods, as calcium can reduce the absorption of the medication.
• Patients should also avoid taking antacids, mineral supplements, or any products containing polyvalent cations (e.g., iron, calcium, aluminum, magnesium) within 4 hours of taking Eltrombopag.

Patients should consult their healthcare provider for personalized dosing and monitoring plans.

Side effects:

Eltrombopag can cause side effects that range from mild to severe. It is important for patients to be aware of these potential side effects and to consult their healthcare provider if they experience any unusual symptoms.

Common Side Effects:

• Nausea
• Diarrhea
• Headache
• Fatigue
• Muscle aches (myalgia)
• Upper respiratory tract infections
• Cough
• Abdominal pain
• Loss of appetite

Long-term side effects:

• Liver Problems:
• Thromboembolic Events:
• Cataracts:
• Bone Marrow Changes:
• Severe Hypersensitivity Reactions:
• Hematologic Malignancies

Use During Pregnancy:

The medicine should be use during pregnancy only if other treatments have not worked and if the potential benefits to the mother outweigh the risks to the baby. This may be necessary in severe conditions such as chronic immune thrombocytopenia (ITP), which can be dangerous for both mother and baby if left untreated.

It is not known whether Eltrom passes into breast milk. Because it could potentially harm the baby, you should stop taking the drug or stop breastfeeding, depending on how important the drug is to the mother’s health.

FDA Approval:

• Initial Approval (2008):

It was first approved by the FDA in November 2008 under the brand name Promacta (marketed by Novartis) for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who have had an insufficient response to corticosteroids, immunoglobulins.

• Expanded Approval (2014):

In August 2014, the FDA expanded the approval of Eltrombopag to include treatment for severe aplastic anemia (SAA) in patients who have had an insufficient response to immunosuppressive therapy. This was significant as it provided a new treatment option for a rare and serious condition.

• Approval for Pediatric Use (2015):

In June 2015, the FDA approved Eltrombopag for the treatment of chronic ITP in pediatric patients aged 1 year and older. This expanded the use of the drug to younger populations suffering from chronic ITP.

Manufacturer:

The manufacturer of Eltrombopag is Novartis Pharmaceuticals Corporation. Novartis is a global healthcare company that develops and markets medications across various therapeutic areas. Eltrombopag is marketed under Promacta in the United States and Revolade in other countries.

Delivery Countries List:

United States, Canada, Mexico, Brazil, Argentina, United Kingdom, France, Germany, Italy, Spain, Portugal, Netherlands, Belgium, Switzerland, Austria, Sweden, Norway, Denmark, Finland, Iceland, Russia, China, Japan, South Korea, North Korea, Vietnam, Thailand, Malaysia, Singapore, Indonesia, Philippines, Australia, New Zealand, South Africa, Egypt, Nigeria, Kenya, Ethiopia, Morocco, Turkey, Saudi Arabia, United Arab Emirates, Iran, Iraq, Syria, Lebanon, Jordan, Qatar, Bahrain, Kuwait, Oman, Yemen, Afghanistan, Sri Lanka, Nepal, Bhutan, Maldives, Myanmar, Cambodia, Laos, Mongolia, Kazakhstan, Uzbekistan, Turkmenistan, Kyrgyzstan, Tajikistan, Azerbaijan, Armenia, Georgia, Ukraine, Belarus, Poland, Czech Republic, Slovakia, Hungary, Romania, Bulgaria, Greece, Albania, Serbia, Montenegro, Bosnia and Herzegovina, Croatia, Slovenia, North Macedonia, Kosovo, Malta, Cyprus, Tunisia, Algeria, Libya, Sudan, Sierra Leone, Liberia, Ivory Coast, Ghana, Uganda, Zambia, Malawi, Zimbabwe, Namibia, Angola, Somalia, Eritrea.

For more medicine, Visit Our Shop